Kite, a Gilead Company, focuses its investment and strategy on developing and commercializing cell therapies, primarily CAR T-cell therapies, to treat life-threatening cancers. The company employs a strategy of both internal innovation and strategic partnerships, including acquisitions, to expand its pipeline and advance next-generation cell therapies like in vivo CAR T and allogeneic therapies.
67% of their portfolio is in Biotech & Life Sciences. They made 1 investments in the last 12 months. Their most common stage is series-c (67% of deals). Average disclosed round size is $64.3M (across 3 rounds with reported amounts).
Portfolio
3
Fund Size
$11.9B
Top Stage
Series C
Last 12 Mo
1
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
3 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Aspen Neuroscience | Series C | $115M | Nov 2025 |
 Shoreline Biosciences | Series B | $43M | Apr 2021 |
 Vineti | Series C | $35M | Feb 2020 |
Top Co-Investors
Cormorant Asset Management2 shared
Lifeforce Capital2 shared
Commodore Capital1 shared
Janus Henderson Investors1 shared
Logos Capital1 shared
Wedbush Healthcare Partners1 shared
Canaan Partners1 shared
Cardinal Health1 shared
Novartis Pharma AG1 shared
Threshold Ventures1 shared
Section 321 shared
Casdin Capital1 shared
Hive Ventures1 shared
OrbiMed1 shared
ARCH Venture Partners1 shared
Frazier Life Sciences1 shared
S321 shared
Balyasny Asset Management1 shared
Axon Partners Group1 shared
Last updated: 10 April 2026